BackgroundPatients with mitral valve (MV) disease and atrial fibrillation (AF) undergo simultaneous prosthetic valve replacement and radiofrequency (RF) ablation procedure; however, this combinational procedure restores sinus rhythm (SR) in only 68–82% of the cases. In patients with ineffective surgical ablation, the use of a biological prosthetic valve might not only be a good choice to perform safe catheter ablation procedure in the left atrium (LA), but also provide a way to discontinue administration of oral anticoagulants. The objective of this study was to assess the efficacy of catheter ablation for AF after MV replacement with a biological prosthesis and an ineffective surgical ablation procedure.MethodsTen consecutive patients aged 48 ± 7 years were enrolled in this study. All patients had long-persistent AF associated with a rheumatic valve disease, which was treated by MV replacement with a biological prosthesis and a surgical RF ablation procedure. In the late postoperative period, all the patients had recurrent hemodynamically significant AF, which required repeated cardioversions. From 1 year to 3 years after the surgery, catheter ablation was performed, including reisolation of pulmonary veins (PVs) with the ablation of ganglionic plexi or linear lesions on the roof of the LA and mitral isthmus. The efficacy was assessed at 3 months, 6 months, and 12 months after the procedure.ResultsRestoration of SR during ablation was achieved in all of the cases. In 6–9 months, all the patients were free of arrhythmia. LA stunning manifested by the absence or decrease of the “A” wave in the transmitral flow and the retrograde wave in the PV flow was observed in nine patients with SR. In five of the patients, LA contractile function was restored in 1–6 months. Prosthetic valve dysfunction was not detected in any of the patients.ConclusionCatheter ablation is an effective method for AF treatment following an ineffective surgical RF ablation procedure and biological prosthetic MV replacement. The use of bioprosthetic MVs allows for performing safe catheter ablation without subsequent prosthetic dysfunction
Chronic heart failure (CHF) is an urgent public health problem. Despite the introduction of modern treatment methods, we can emphasize high morbidity, mortality and frequent repeated hospitalizations in patients with heart failure. Significant causes of repeated hospitalizations for CHF are insufficient continuity in healthcare system and low adherence to outpatient treatment. A rational and low-cost way to solve these problems are interacting CHF centers at all levels of health care including CHF rooms in each polyclinic and joint outpatient management by doctors and nurse practitioners. The authors present the results of advanced medical care for chronic heart failure in different regions of the Russian Federation for the period 2020—2022. In the first part, they present and analyze data from the CHF registers of the Tula, Sverdlovsk, Chelyabinsk, Tyumen, Kemerovo and Perm regions taking into account regional characteristics and opportunities.
Применение сервиса поддержки принятия врачебных решений (СППВР) для работы с большим количеством цифровых данных, таких как электронные медицинские карты (ЭМК), может сыграть важную роль в улучшении качества оказываемой медицинской помощи. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить перспективы проведения автоматизированного анализа при помощи СППВР соответствия критериев отбора пациентов для катетерной аблации по поводу фибрилляции предсердий (ФП) данным в электронных медицинских картах (ЭМК) среди карт в группах повторной и первичной процедур в реальной клинической практике крупных медицинских центров. МАТЕРИАЛ И МЕТОДЫ Проанализированы ЭМК 232 пациентов, направленных на катетерную аблацию легочных вен по поводу ФП. Основными предикторами рецидива ФП при автоматическом анализе СППВР считались следующие характеристики: возраст, индекс массы тела (ИМТ) и продольный размер левого предсердия (ЛП) по эхокардиографическим данным. РЕЗУЛЬТАТЫ У 137 (59,1%) пациентов, направленных на катетерную аблацию, не имелось предикторов рецидива ФП. Аблация в анамнезе была у 141 (60,8%) пациента. Риск рецидива аритмии выявлен у 49,5% пациентов, направленных на первичную процедуру, и у 36,2% пациентов из группы повторной аблации. ЭМК с прогнозируемым риском рецидива ФП по возрастному критерию составили 14,3% в группе первичной аблации и 5,7% в группе повторной аблации (p=0,026). Доля ЭМК пациентов с прогнозируемым риском рецидива ФП по критерию ИМТ составила 17,6% в группе первичной аблации и 17,7% в группе повторной аблации (p=0,977). Увеличенный размер ЛП был выявлен в качестве прогнозируемого условия рецидива ФП в 26,4% случаев в группе первичной аблации и 18,4% в группе повторной аблации (p=0,152). ЗАКЛЮЧЕНИЕ Среди пациентов с показаниями для катетерной аблации с целью устранения фибрилляции предсердий существенную долю составляют лица с рецидивами аритмии после предыдущих катетерных вмешательств. Отбор пациентов на повторные вмешательства проводится более тщательно. Необходимы современные цифровые инструменты для отбора пациентов на катетерные методы лечения, что может снизить количество повторных процедур и рецидивов ФП.
25 March 2022 in Complex Issues of Cardiovascular Diseases
Highlights. Patient education program developed for patients with prosthetic heart valves, which includes information on the anticoagulant therapy, prevention of prosthetic valve endocarditis, and physical and psychological rehabilitation, helps to improve adherence to treatment and quality of life immediately upon completion of training (6 months). The quality of life and adherence to treatment were higher at 10-year follow-up in patients undergoing full course of training, in inpatient and outpatient settings, compared with patients undergoing training in inpatient setting only.Aim. To evaluate the efficacy of the training program for patients with prosthetic heart valves in improving treatment adherence and quality of life at 10-year follow-up.Methods. Patient education program entitled “School for patients with prosthetic heart valves” was developed and implemented at the Research Institute for Complex Issues of Cardiovascular Diseases (Kemerovo) in 2010. The program provides knowledge and training regarding anticoagulant therapy, prevention of prosthetic valve endocarditis, physical and psychological rehabilitation. The training group consisted of 92 patients who completed a full course of training (6 months). The control group included 56 patients who completed training in inpatient setting only. Long-term efficacy of the developed education program was assessed at 10-year follow-up via evaluation of the indicators of adherence to treatment (questionnaire for determining the integral indicator of adherence to treatment (IIAT)) and the quality of life (using Short-Form 36-item questionnaire (SF-36)).Results. Initially, data analysis showed no statistically significant differences between the groups in the quality of life and adherence to treatment. Six months later the IIAT score in the training group (full course of training) was 9.15±1.16, in controls the score was 6.20±1.05 (р = 0.0001). Highest IIAT scores in the training group remained similar (8.10±1.20 points) at 10-year follow-up, in the control group it was lower - 5.19±1.09 (р = 0.0001). After 6 months, physical component summary score increased by 24% over baseline in controls (р = 0.0001) and by 25% in the training group (р = 0.0001). After 6-month follow-up, there was an improvement in the psychological component summary score by 14.5% (р = 0.0001) in the control group and by 42.8% in the training group (р = 0.0001). 10 years after completion of training, physical component and mental component summary scores were higher in patients undergoing full training course - 8.3% (р = 0.0001) and 14.3% (р = 0.0001), respectively.Conclusion. Patient education program “School for patients with prosthetic heart valves” via full course of training increases levels of adherence to treatment and quality of life mainly due to improvement of psychological component summary score in the early period (6 months) and at 10-year follow-up.